Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality. Since sleep ...

Tirzepatide includes blockbuster injected GLP-1 meds Mounjaro (for diabetes) and Zepbound (for weight loss ... new government data shows. Sleep apnea is known to wreak havoc on the body and ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. Eli Lilly said the FDA approved Zepbound for moderate-to-severe ...

Sleep disordered breathing is a range of conditions that cause abnormal breathing during sleep including snoring and obstructive sleep apnea. Obstructive sleep apnea is when a person stops ...

Sleep apnea, a widespread health issue, causes breathing interruptions during sleep, leading to oxygen deprivation and various health problems. It manifests in obstructive, central, and mixed forms.

Share on Pinterest A new study links sleep apnea to changes in key brain regions related to memory. Image credit: Maskot/Getty Images. About 936 million adults around the world have sleep apnea.